TrialJournal of neural transmission (Vienna, Austria : 1996)2012

The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial.

Tamar Green et al.PubMed ↗Publisher ↗

No numbers read from the abstract.